Biocept Inc (BIOC) 1.41 $BIOC
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:45AM CST
CYTK: 7.78 (+1.29), MNOV: 3.62 (-0.56), MX: 7.52 (-7.50), SIEB: 1.71 (-0.24), QKLS: 2.10 (-0.24), YUMA: 1.88 (+0.67), CYBR: 52.52 (+6.83), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), CECO: 5.34 (-0.92), GENE: 8.04 (+1.90), SGNL: 3.91 (+2.15), IMI: 1.70 (-0.20), RCKY: 18.43 (+4.33), WAC: 20.29 (+2.57), FNJN: 2.77 (-0.36), ZNGA: 2.24 (-0.42), PRAN: 1.09 (-0.55)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HNNA: 24.40 (+0.40), OFED: 20.41 (+0.16), DLHC: 2.21 (-0.06), BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), BIOC: 1.41 (+0.22), NWFL: 30.00 (+0.25), ATOS: 1.67 (+0.11), SPDC: 1.18 (+0.05), FSC: 7.23 (+0.12), OVBC: 24.00 (unch), QTWW: 2.96 (-0.04), ANTH: 3.84 (+0.06), IMI: 1.70 (-0.20), FBMS: 14.69 (+0.31), EXA: 10.46 (+0.09), FNJN: 2.77 (-0.36)
Biocept (BIOC) Stock Plummets Today After Pricing Public Offering, Warrants
at The Street - Tue Feb 10, 12:21PM CST
Shares of Biocept (BIOC) are down after the company announced the pricing of 8 million shares of its common stock and warrants at a combined offering price of $1.25.
BIOC: 1.41 (+0.22)
Biocept prices offering
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 10:52AM CST
BIOC: 1.41 (+0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Biocept, Inc. Prices $10,000,000 Public Offering
GlobeNewswire - Mon Feb 09, 5:21PM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock and warrants to purchase up to an aggregate of 8,000,000 shares of its common stock at a combined offering price of $1.25. The warrants will have a per share exercise price of $1.56, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Biocept has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares of common stock and/or 1,200,000 additional warrants to cover over-allotments, if any. The offering is expected to close on February 13, 2015, subject to customary closing conditions.
BIOC: 1.41 (+0.22)
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 4.04 (+0.01), SHAK: 40.69 (+0.04), BRDR: 6.15 (+0.04), ECR: 7.29 (+0.12), BIOC: 1.41 (+0.22), ATEN: 4.14 (-0.09), CRCM: 7.98 (-0.07), AMDA: 0.65 (+0.01), MOLG: 2.46 (+0.03), SGNL: 3.91 (+2.15), GBSN: 1.77 (-0.08), FMSA: 6.23 (+0.29), HELI: 2.11 (+0.03), REPH: 3.13 (-0.12)
Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer
GlobeNewswire - Tue Jan 20, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced the launch of ROS1 testing on CTCs, which will help physicians identify which of their patients may be receptive to certain drugs for the treatment of non-small cell lung cancer.
BIOC: 1.41 (+0.22)
Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients
GlobeNewswire - Mon Jan 12, 8:16AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced the launch of its EGFR mutation test that targets a region of the gene that includes T790M, a biomarker that identifies therapy-resistant tumors utilizing its proprietary Selector technology. This test will be performed at the Company's CLIA-certified and CAP-accredited laboratory and is the first of several assays the company will launch based on its proprietary Selector platform. The launch of Selector technology for ctDNA biomarker analysis from plasma in non-small cell lung cancer (NSCLC) expands Biocept's existing test menu of commercialized blood based assays for CTC capture and analysis for breast, gastric and lung cancers. The Selector technology was developed and validated by scientists at Biocept.
BIOC: 1.41 (+0.22)
Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment
GlobeNewswire - Thu Jan 08, 7:50AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs); and Insight Genetics, a leading molecular diagnostic assay development company, today announced their collaboration to generate an enhanced diagnostic for the expression and mutation of ALK, a major therapeutic target in the treatment of non-small cell lung cancer.
BIOC: 1.41 (+0.22)
Biocept to Present at the 8th Annual OneMedForum
GlobeNewswire - Wed Jan 07, 8:00AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 8 Annual OneMedForum 2015 on Tuesday, January 13 at 2:40 PM PT at the Marriot Marquis Hotel in San Francisco.
BIOC: 1.41 (+0.22)
Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network
GlobeNewswire - Wed Jan 07, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) testing, today announced that its proprietary liquid biopsy testing that is performed at the Company's CLIA-certified and CAP-accredited laboratory will be offered to participants in the America's Choice Provider Network (ACPN), a Preferred Provider Organization (PPO).
BIOC: 1.41 (+0.22)
Worst Performing IPOs of 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:10AM CST
The average offering return was at 16% in 2014, significantly lower than 41% in 2013
E: 36.31 (+0.69), SC: 22.11 (+0.38), ALLY: 22.05 (+0.21), FB: 75.74 (-0.49), BIOC: 1.41 (+0.22), NADL: 2.10 (-0.02), RBS: 11.97 (+0.01), ATEN: 4.14 (-0.09), V: 269.63 (-1.28), CFG: 25.45 (+0.12), SYF: 32.80 (-0.81), PGRE: 18.54 (-0.11), NDAQ: 49.48 (-0.27), AM: 24.47 (+0.64), REPH: 3.13 (-0.12), BABA: 89.05 (+1.95)
Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells
GlobeNewswire - Wed Dec 17, 8:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), today announced the presentation of a poster at the 2014 San Antonio Breast Cancer Symposium. The presentation highlights Biocept's ability to identify patients who have developed HER2-positive CTCs during disease progression after an initial HER2-negative diagnosis by solid biopsy. The discovery of these patients, who may potentially be candidates for anti-HER2 treatment is made possible by OncoCEE-BR(TM), a breast cancer diagnostic developed using Biocept's CTC capture and analysis technology. The study was conducted at the Dana-Farber/Harvard Cancer Center.
BIOC: 1.41 (+0.22)
Biocept Expands Worldwide Microchannel Patent Protection to South Korea
GlobeNewswire - Mon Dec 15, 8:05AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that it has been granted a patent in South Korea for its fluidic microfluidic channel. The patent, Detection or Isolation of Target Molecules Using a Microchannel Apparatus, is the subject of Korean Patent Application No. 10-2009-7003339.
BIOC: 1.41 (+0.22)
Biocept Appoints Experienced Physician as Medical Director
GlobeNewswire - Wed Dec 03, 8:24AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Veena Singh, MD, FCAP, FCAMG has joined the Company as Senior Vice President and Senior Medical Director.
BIOC: 1.41 (+0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 11:45AM CST
CYTK: 7.78 (+1.29), MNOV: 3.62 (-0.56), MX: 7.52 (-7.50), SIEB: 1.71 (-0.24), QKLS: 2.10 (-0.24), YUMA: 1.88 (+0.67), CYBR: 52.52 (+6.83), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), BIOC: 1.41 (+0.22), NBG: 1.61 (+0.18), CECO: 5.34 (-0.92), GENE: 8.04 (+1.90), SGNL: 3.91 (+2.15), IMI: 1.70 (-0.20), RCKY: 18.43 (+4.33), WAC: 20.29 (+2.57), FNJN: 2.77 (-0.36), ZNGA: 2.24 (-0.42), PRAN: 1.09 (-0.55)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 10, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HNNA: 24.40 (+0.40), OFED: 20.41 (+0.16), DLHC: 2.21 (-0.06), BELFB: 23.44 (+0.60), BELFA: 19.90 (-0.40), BIOC: 1.41 (+0.22), NWFL: 30.00 (+0.25), ATOS: 1.67 (+0.11), SPDC: 1.18 (+0.05), FSC: 7.23 (+0.12), OVBC: 24.00 (unch), QTWW: 2.96 (-0.04), ANTH: 3.84 (+0.06), IMI: 1.70 (-0.20), FBMS: 14.69 (+0.31), EXA: 10.46 (+0.09), FNJN: 2.77 (-0.36)
Biocept (BIOC) Stock Plummets Today After Pricing Public Offering, Warrants
at The Street - Tue Feb 10, 12:21PM CST
Shares of Biocept (BIOC) are down after the company announced the pricing of 8 million shares of its common stock and warrants at a combined offering price of $1.25.
BIOC: 1.41 (+0.22)
Biocept prices offering
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 10:52AM CST
BIOC: 1.41 (+0.22)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Biocept, Inc. Prices $10,000,000 Public Offering
GlobeNewswire - Mon Feb 09, 5:21PM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and circulating tumor cells, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock and warrants to purchase up to an aggregate of 8,000,000 shares of its common stock at a combined offering price of $1.25. The warrants will have a per share exercise price of $1.56, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Biocept from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. Biocept has granted the underwriters a 45-day option to purchase up to an additional 1,200,000 shares of common stock and/or 1,200,000 additional warrants to cover over-allotments, if any. The offering is expected to close on February 13, 2015, subject to customary closing conditions.
BIOC: 1.41 (+0.22)
13 IPOs You Wish You Didn't Buy in 2014 (And Killed Your Portfolio)
at The Street - Fri Feb 06, 11:55AM CST
Here are the 13 worst performing IPO stocks in 2014.
ROKA: 4.04 (+0.01), SHAK: 40.69 (+0.04), BRDR: 6.15 (+0.04), ECR: 7.29 (+0.12), BIOC: 1.41 (+0.22), ATEN: 4.14 (-0.09), CRCM: 7.98 (-0.07), AMDA: 0.65 (+0.01), MOLG: 2.46 (+0.03), SGNL: 3.91 (+2.15), GBSN: 1.77 (-0.08), FMSA: 6.23 (+0.29), HELI: 2.11 (+0.03), REPH: 3.13 (-0.12)
Biocept Introduces New Test for Patients With Non-Small Cell Lung Cancer
GlobeNewswire - Tue Jan 20, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced the launch of ROS1 testing on CTCs, which will help physicians identify which of their patients may be receptive to certain drugs for the treatment of non-small cell lung cancer.
BIOC: 1.41 (+0.22)
Biocept Launches Selector(TM), a Blood Based Test for EGFR Mutations for Non-Small Cell Lung Cancer Patients
GlobeNewswire - Mon Jan 12, 8:16AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), today announced the launch of its EGFR mutation test that targets a region of the gene that includes T790M, a biomarker that identifies therapy-resistant tumors utilizing its proprietary Selector technology. This test will be performed at the Company's CLIA-certified and CAP-accredited laboratory and is the first of several assays the company will launch based on its proprietary Selector platform. The launch of Selector technology for ctDNA biomarker analysis from plasma in non-small cell lung cancer (NSCLC) expands Biocept's existing test menu of commercialized blood based assays for CTC capture and analysis for breast, gastric and lung cancers. The Selector technology was developed and validated by scientists at Biocept.
BIOC: 1.41 (+0.22)
Biocept and Insight Genetics Collaborate to Advance Non-Small Cell Lung Cancer Diagnosis and Treatment
GlobeNewswire - Thu Jan 08, 7:50AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs); and Insight Genetics, a leading molecular diagnostic assay development company, today announced their collaboration to generate an enhanced diagnostic for the expression and mutation of ALK, a major therapeutic target in the treatment of non-small cell lung cancer.
BIOC: 1.41 (+0.22)
Biocept to Present at the 8th Annual OneMedForum
GlobeNewswire - Wed Jan 07, 8:00AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 8 Annual OneMedForum 2015 on Tuesday, January 13 at 2:40 PM PT at the Marriot Marquis Hotel in San Francisco.
BIOC: 1.41 (+0.22)
Biocept's Proprietary Oncology Diagnostics to be Offered on America's Choice Provider Network
GlobeNewswire - Wed Jan 07, 7:30AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) testing, today announced that its proprietary liquid biopsy testing that is performed at the Company's CLIA-certified and CAP-accredited laboratory will be offered to participants in the America's Choice Provider Network (ACPN), a Preferred Provider Organization (PPO).
BIOC: 1.41 (+0.22)
Worst Performing IPOs of 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:10AM CST
The average offering return was at 16% in 2014, significantly lower than 41% in 2013
E: 36.31 (+0.69), SC: 22.11 (+0.38), ALLY: 22.05 (+0.21), FB: 75.74 (-0.49), BIOC: 1.41 (+0.22), NADL: 2.10 (-0.02), RBS: 11.97 (+0.01), ATEN: 4.14 (-0.09), V: 269.63 (-1.28), CFG: 25.45 (+0.12), SYF: 32.80 (-0.81), PGRE: 18.54 (-0.11), NDAQ: 49.48 (-0.27), AM: 24.47 (+0.64), REPH: 3.13 (-0.12), BABA: 89.05 (+1.95)
Biocept's Patented Platform Identifies Clinically HER2-Negative Patients With HER2-Positive Circulating Tumor Cells
GlobeNewswire - Wed Dec 17, 8:35AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), today announced the presentation of a poster at the 2014 San Antonio Breast Cancer Symposium. The presentation highlights Biocept's ability to identify patients who have developed HER2-positive CTCs during disease progression after an initial HER2-negative diagnosis by solid biopsy. The discovery of these patients, who may potentially be candidates for anti-HER2 treatment is made possible by OncoCEE-BR(TM), a breast cancer diagnostic developed using Biocept's CTC capture and analysis technology. The study was conducted at the Dana-Farber/Harvard Cancer Center.
BIOC: 1.41 (+0.22)
Biocept Expands Worldwide Microchannel Patent Protection to South Korea
GlobeNewswire - Mon Dec 15, 8:05AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that it has been granted a patent in South Korea for its fluidic microfluidic channel. The patent, Detection or Isolation of Target Molecules Using a Microchannel Apparatus, is the subject of Korean Patent Application No. 10-2009-7003339.
BIOC: 1.41 (+0.22)
Biocept Appoints Experienced Physician as Medical Director
GlobeNewswire - Wed Dec 03, 8:24AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Veena Singh, MD, FCAP, FCAMG has joined the Company as Senior Vice President and Senior Medical Director.
BIOC: 1.41 (+0.22)
